Journal
BIOCHEMICAL JOURNAL
Volume 460, Issue -, Pages 127-139Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BJ20140334
Keywords
Parkin; Parkinson's disease; phosphorylation; PTEN (phosphatase and tensin homologue deleted on chromosome; 10)-induced putative kinase 1 (PINK1); ubiquitin
Categories
Funding
- Medical Research Council (MRC)
- Wellcome Trust
- Parkinson's UK
- Michael J. Fox Foundation for Parkinson's disease research
- Wellcome Trust/Medical Research Council (MC) PD (Parkinson's disease) consortium
- J. Macdonald Menzies Charitable Trust Prize Studentship
- Wellcome Trust Senior Research Fellowship in Clinical Science [101022/Z/13/Z]
- Division of Signal Transduction Therapy Unit (AstraZeneca)
- Boehringer-Ingelheim
- GlaxoSmithKline
- Merck KGaA
- Janssen Pharmaceutica
- Pfizer
- MRC [MC_G1000735, MC_UP_A500_1020, MC_UU_12016/2, G1100713, MC_UU_12016/5] Funding Source: UKRI
- Medical Research Council [MC_UP_A500_1020, G1100713, MC_UU_12016/2, MC_UU_12016/5, MC_G1000735] Funding Source: researchfish
- Parkinson's UK [H-1101, H-0901] Funding Source: researchfish
Ask authors/readers for more resources
We have previously reported that the Parkinson's disease-associated kinase PINK1 (PTEN-induced putative kinase 1) is activated by mitochondrial depolarization and stimulates the Parkin E3 ligase by phosphorylating Ser(65) within its Ubl (ubiquitin-like) domain. Using phosphoproteomic analysis, we identified a novel ubiquitin phosphopeptide phosphorylated at Ser(65) that was enriched 14-fold in HEK (human embryonic kidney)-293 cells overexpressing wild-type PINK1 stimulated with the mitochondrial uncoupling agent CCCP (carbonyl cyanide m-chlorophenylhydrazone), to activate PINK1, compared with cells expressing kinase-inactive PINK1. Ser(65) in ubiquitin lies in a similar motif to Ser(65) in the Ubl domain of Parkin. Remarkably, PlNK1 directly phosphorylates Ser(65) of ubiquitin in vitro. We undertook a series of experiments that provide striking evidence that Ser(65)-phosphorylated ubiquitin (ubiquitin(Phospho-Ser65)) functions as a critical activator of Parkin. First, we demonstrate that a fragment of Parkin lacking the Ubl domain encompassing Ser(65) (Delta Ubl-Parkin) is robustly activated by ubiquitin(Phospho-Ser65), but not by non-phosphorylated ubiquitin. Secondly, we find that the isolated Parkin Ubl domain phosphorylated at Ser(65) (Ubl(phospho-Ser65)) can also activate Delta Ubl-Parkin similarly to ubiquitin(PhosPh-Ser65). Thirdly, we establish that ubiquitin(PhosPh-Ser65), but not non-phosphorylated ubiquitin or Ubl(PhosPh-Ser65) activates full-length wild-type Parkin as well as the non-phosphorylatable S65A Parkin mutant. Fourthly, we provide evidence that optimal activation of full-length Parkin E3 ligase is dependent on PINK1-mediated phosphorylation of both Parkin at Ser(65) and ubiquitin at Ser(65), since only mutation of both proteins at Ser(65) completely abolishes Parkin activation. In conclusion, the findings of the present study reveal that PINK1 controls Parkin E3 ligase activity not only by phosphorylating Parkin at Ser(65), but also by phosphorylating ubiquitin at Ser(65). We propose that phosphorylation of Parkin at Ser(65) serves to prime the E3 ligase enzyme for activation by ubiquitin(PhosPh-Ser65), suggesting that small molecules that mimic ubiquitin(PhosPh-Ser65) could hold promise as novel therapies for Parkinson's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available